Evaluating the potency of HIV-1 protease drugs to combat resistance

Proteins: Structure, Function and Genetics

Volumn 71, Issue 3, 2008, Pages 1163-1174

  Hou, Tingjun ^a   McLaughlin, William A ^a   Wang, Wei ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Darunavir; Drug resistance; HIV 1 protease; MM GBSA; Molecular dynamics simulations

Indexed keywords

AMPRENAVIR; DARUNAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; RITONAVIR; SAQUINAVIR; TIPRANAVIR; VIRUS ENZYME;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; MUTATION; PREDICTIVE VALUE OF TESTS; SULFONAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 42449147045     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21808     Document Type: Article

References (49)

1. Darke PL, Nutt RF, Brady SF, Garsky VM, Ciccarone TM, Leu CT, Lumma PK, Freidinger RM, Veber DF, Sigal IS. HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem Bioph Res Co 1988;156:297-303.
2. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RAF, Scolnick EM, Sigal IS. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988;85:4686-4690.
3. Miller M, Jaskolski M, Rao JKM, Leis J, Wlodawer A. Crystal-structure of a retroviral protease proves relationship to aspartic protease family. Nature 1989;337:576-579.
4. Swain AL, Miller MM, Green J, Rich DH, Schneider J, Kent SBH, Wlodawer A. X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus-1 and a substrate-based hydroxyethylamine inhibitor. Proc Natl Acad Sci USA 1990;87:8805-8809.
5. Clavel F, Hance AJ. Medical progress: HIV drug resistance. New Engl J Med 2004;350:1023-1035.
6. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Teppler H, Squires KE, Deutsch PJ, Emini EA. Invivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-571.
7. Kaplan AH, Michael SF, Wehbie RS, Knigge MF, Paul DA, Everitt L, Kempf DJ, Norbeck DW, Erickson JW, Swanstrom R. Selection of multiple human-immunodeficiency-virus type-1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci USA 1994;91:5597-5601.
8. Shafer RW, Stevenson D, Chan B. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 1999;27:348-352.
9. Cao ZW, Han LY, Zheng CJ, Ji ZL, Chen X, Lin HH, Chen YZ. Computer prediction of drug resistance mutations in proteins. Drug Discov Today 2005;10:521-529.
10. Wang W, Donini O, Reyes CM, Kollman PA. Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions. Annu Rev Biophys Biomol 2001;30:211-243.
11. Boutton CW, De Bondt HL, De Jonge MR. Genotype dependent QSAR for HIV-1 protease inhibition. J Med Chem 2005;48:2115-2120.
12. Shenderovich MD, Kagan RM, Heseltine PNR, Ramnarayan K. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance. Protein Sci 2003;12:1706-1718.
13. Chen YZ, Gu XL, Cao ZW. Can an optimization/scoring procedure in ligand-protein docking be employed to probe drug-resistant mutations in proteins? J Mol Graph Model 2001;19:560-570.
14. Nair AC, Bonin I, Tossi A, Welsh WJ, Miertus S. Computational studies of the resistance patterns of mutant HIV-1 aspartic proteases towards ABT-538 (ritonavir) and design of new derivatives. J Mol Graph Model 2002;21:171-179.
15. Hou TJ, Yu R. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. J Med Chem 2007;50:1177-1188.
16. Wang W, Kollman PA. Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc Natl Acad Sci USA 2001;98:14937-14942.
17. Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 2002;10:369-381.
18. Lee MS, Olson MA. Calculation of absolute protein-ligand binding affinity using path and endpoint approaches. Biophys J 2006;90: 864-877.
19. King NM, Prabu-Jeyabalan M, Nalivaika EA, Schiffer CA. Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem Biol 2004;11:1333-1338.
20. Wittayanarakul K, Aruksakunwong O, Saen-oon S, Chantratita W, Parasuk V, Sompornpisut P, Hannongbua S. Insights into saquinavir resistance in the G48V HIV-1 protease: quantum calculations and molecular dynamic simulations. Biophys J 2005;88:867-879.
21. Ohtaka H, Velazquez-Campoy A, Xie D, Freire E. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci 2002;11:1908-1916.
22. Sorbera LA, Castaner J, Bayes M. Darunavir-anti-HIV agent HIV protease inhibitor. Drug Future 2005;30:441-449.
23. Surleraux DLNG, Tahri A, Verschueren WG, Pille GME, de Kock HA, Junckers THM, Peeters A, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PBTP. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem 2005;48:1813-1822.
24. Wang W, Kollman PA. Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc Natl Acad Sci USA 2001;98:14937-14942.
25. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Res 2000;28:235-242.
26. Krohn A, Redshaw S, Ritchie JC, Graves BJ, Hatada MH. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J Med Chem 1991;34: 3340-3342.
27. Chen ZG, Li Y, Chen E, Hall DL, Darke PL, Culberson C, Shafer JA, Kuo LC. Crystal-structure at 1.9-angstrom resolution of human-immunodeficiency-virus (HIV)-Ii protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J Biol Chem 1994;269:26344-26348.
28. Kempf DJ, Marsh KC, Denissen JF, Mcdonald E, Vasavanonda S, Flentge CA, Green BE, Fino L, Park CH, Kong XP, Wideburg NE, Saldivar A, Ruiz L, Kati WM, Sham HL, Robins T, Stewart KD, Hsu A, Plattner JJ, Leonard JM, Norbeck DW. Abt-538 is a potent inhibitor of human-immunodeficiency-virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995;92:2484-2488.
29. Kaldor SW, Kalish VJ, Davies JF, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH. Viracept (nelfinavir mesylate. AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem 1997;40:3979-3985.
30. Kim EE, Baker CT, Dwyer MD, Murcko MA, Rao BG, Tung RD, Navia MA. Crystal-structure of HIV-1 protease in complex with Vx-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc 1995;117:1181-1182.
31. Stoll V, Qin WY, Stewart KD, Jakob C, Park C, Walter K, Simmer RL, Helfrich R, Bussiere D, Kao J, Kempf D, Sham HL, Norbeck DW. X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease. Bioorgan Med Chem 2002;10:2803-2806.
32. Thaisrivongs S, Skulnick HI, Turner SR, Strohbach JW, Tommasi RA, Johnson PD, Aristoff PA, Judge TM, Gammill RB, Morris JK, Romines KR, Chrusciel RA, Hinshaw RR, Chong KT, Tarpley WG, Poppe SM, Slade DE, Lynn JC, Horng MM, Tomich PK, Seest EP, Dolak LA, Howe WJ, Howard GM, Schwende FJ, Toth LN, Padbury GE, Wilson GJ, Shiou LH, Zipp GL, Wilkinson KF, Rush BD, Ruwart MJ, Koeplinger KA, Zhao ZY, Cole S, Zaya RM, Kakuk TJ, Janakira-man MN, Watenpaugh KD. Structure-based design of HIV protease Inhibitors: Sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem 1996;39:4349-4353.
33. Nichols CE, Hawkins AR, Stammers DK. Structure of the 'open' form of Aspergillus nidulans 3-dehydroquinate synthase at 1.7 angstrom resolution from crystals grown following enzyme turnover. Acta Crystallogr D 2004;60:971-973.
34. SYBYL molecular simulation package, http://www.sybyl.com. 2004.
35. Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Onufriev A, Simmerling C, Wang B, Woods RJ. The Amber biomolecular simulation programs. J Comput Chem 2005;26:1668-1688.
36. Hyland LJ, Tomaszek TA, Meek TD. Human immunodeficiency virus-1 protease. II. Use of Ph rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry-US 1991;30:8454-8463.
37. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong GM, Zhang W, Yang R, Cieplak P, Luo R, Lee T, Caldwell J, Wang JM, Kollman P. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 2003;24:1999-2012.
38. Wang JM, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem 2004;25:1157-1174.
39. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Zakrzewski VG, Montgomery JAJ, Stratmann RE, Burant JC, Dapprich S, Millam JM, Daniels AD, Kudin KN, Strain MC, Farkas O, Tomasi J, Barone V, Cossi M, Cammi R, Mennucci B, Pomelli C, Adamo C, Clifford S, COshterski J, Petersson GA, Ayala PY, Cui Q, Morokuma K, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Cioslowski J, Ortiz JV, Baboul AG, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Gomperts R, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Gonzalez C, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Andres JL, Gonzalez C, Head-Gordon M, Replogle ES, Pople JA. Gaussian 98. Pittsburgh, PA: Gaussian, 1998.
40. Bayly CI, Cieplak P, Cornell WD, Kollman PA. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges - the Resp model. J Phys Chem-US 1993;97:10269-10280.
41. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983;79:926-935.
42. Darden T, York D, Pedersen L. Particle mesh ewald - an NLog(N) method for ewald sums in large systems. J Chem Phys 1993;98: 10089-10092.
43. Berendsen HJC, Postma JPM, Vangunsteren WF, Dinola A, Haak JR. Molecular-dynamics with coupling to an external bath. J Chem Phys 1984;81:3684-3690.
44. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical-integration of cartesian equations of motion of a system with constraints - molecular-dynamics of N-alkanes. J Comput Phys 1977;23:327-341.
45. Wang JM, Hou TJ, Xu XJ. Recent advances in free energy calculations with a combination of molecular mechanics and continuum models. Curr Comput-Aided Drug Design 2006;2:287-306.
46. Kollman PA, Massova I, Reyes C, Kuhn B, Huo SH, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Accounts Chem Res 2000;33:889-897.
47. Onufriev A, Bashford D, Case DA. Modification of the generalized Born model suitable for macromolecules. J Phys Chem B 2000;104: 3712-3720.
48. Weiser J, Shenkin PS, Still WC. Approximate solvent-accessible surface areas from tetrahedrally directed neighbor densities. Biopolymers 1999;50:373-380.
49. Gohlke H, Kiel C, Case DA. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RaIGDS complexes. J Mol Biol 2003;330: 891-913.